How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Private European companies enjoy their own treasure bath
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Corporate VC activity in medtech increases – until this year
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
Venture funding slowdown continues in first quarter of 2019
Venture funding drops again, but there’s no need to panic yet.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Biopharma's record venture year ends with a slowdown
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
